Many loyal supporters said the same thing for TLD and JAMA, but it’s ok to live in denial. It went from 1.2 to 60 cents.
It’s likely we go back to 40 cents or lower in the second half of this year before we get any regulatory news. Again, you are welcome to live in denial. Depending on the timing, we are also likely to be around 1.3B outstanding shares before we get UK approval news as dilution accelerates in the coming months due to debts and ongoing operation costs.
So if we are lucky, we double at UK approval to 80 or 90 cents and ultimately shorts slam it down to 60 or 70 cents in subsequent weeks with lack of execution on commercial front. In essence, UK approvals won’t provide the return everyone is expecting for folks who have bought in 60 or 70 cent range. And folks who bought it over a dollar last year will continue to remain in red!
However, a big pharma partner can change the market perception and bring experience, energy and rigor to the fold. That’s where things can change quickly to our benefit. Otherwise, it will be more of the same. The same group who weren’t able to convince the street on the value of DCVAX-L with JAMA, TLD and MIA won’t be able to make any meaningful impact with MHRA approvals either. In my view, UK approval is expected and priced in with this group at the helm given how long this has taken.
News 
Market Data 
Discover 
